Display Settings:

Format

Send to:

Choose Destination

    N Engl J Med. 2009 Feb 12;360(7):692-8.

    Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation.

    Hütter G, Nowak D, Mossner M, Ganepola S, Müssig A, Allers K, Schneider T, Hofmann J, Kücherer C, Blau O, Blau IW, Hofmann WK, Thiel E.

    Department of Hematology, Oncology, and Transfusion Medicine, Campus Benjamin Franklin, Charité Universitätsmedizin Berlin, Germany. gero.huetter@charite.de

    Comment in:

    Infection with the human immunodeficiency virus type 1 (HIV-1) requires the presence of a CD4 receptor and a chemokine receptor, principally chemokine receptor 5 (CCR5). Homozygosity for a 32-bp deletion in the CCR5 allele provides resistance against HIV-1 acquisition. We transplanted stem cells from a donor who was homozygous for CCR5 delta32 in a patient with acute myeloid leukemia and HIV-1 infection. The patient remained without viral rebound 20 months after transplantation and discontinuation of antiretroviral therapy. This outcome demonstrates the critical role CCR5 plays in maintaining HIV-1 infection. 2009 Massachusetts Medical Society

    PMID: 19213682 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Click here to read Click here to read Click here to read Click here to read Click here to read Click here to read